Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.

[1]  G. Fabbrocini,et al.  Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy. , 2018, European journal of cancer.

[2]  E. Hulstaert,et al.  Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review , 2018, Case Reports in Dermatology.

[3]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[4]  K. Peris,et al.  Long‐term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) , 2017, Journal of the American Academy of Dermatology.

[5]  G. Jeudy,et al.  Anti‐PD1‐induced psoriasis: a study of 21 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Toshiyuki Yamamoto,et al.  Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. , 2016, Acta dermato-venereologica.

[8]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jilly F. Evans,et al.  Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.

[10]  C. Punt,et al.  PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer , 2012, Journal of immunotherapy.

[11]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.